Pharma majors, govt to chalk out plan on export growth

10 Jun 2011 Evaluate

Thirty top pharmaceutical exporters that account for almost half of India’s drug exports worth $10 billion (about Rs 45,000 crore) will meet commerce ministry representatives to formulate a growth plan for the sector. Key to the discussion will be the increasing challenge posed by China in the drugs and pharmaceutical segment. Dr Reddys, Ranbaxy, Cipla, Lupin, Cadilla are among the shortlisted firms. The meeting is meant to chalk out ways to help the industry achieve 150 per cent growth in pharma exports to $25 billion in three years, a target set by the ministry as part of its overall strategy to double India’s export revenues during the period. The leading exporters had been chosen after considering their performance in six different export regions as each region pose unique market challenges.

The strategic paper on doubling export revenues talks about a two pronged approach to penetrate the drug export markets. It wants to maintain and where possible enhance market share in regions where India’s presence is already robust such as North America, Africa and the European Union (EU). Government wants to identify countries within the EU and Africa where the rate of growth and market share have been substantially low for renewed focus. Mexico and Brazil are the Latin American countries having a huge export potential. India had gone down from a position of meeting 70 per cent of its bulk drug requirement from indigenous production to just 30 to 40 per cent, with the rest coming from China. Terming India’s low export penetration into China as a concern, the government highlighted the need for critical policy interventions to bring back bulk drug manufacturing to India and to increase India’s presence in China in the formulation sector. Government is also looking at specific strategies to increase the volume of medicine exports to Japan. The exporters are expected to provide insight into the ground level issues in each of these territories to formulate better strategies.

The major demands from pharmaceutical exports are the extension of the Duty Entitled Passbook scheme beyond June 30, 2011, till an alternative is worked out between the government and the stakeholders. Providing financial incentives to exporters is another suggestion. crack crack

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

PROPRIETARY FRAMEWORK

Portfolio
Architecture >
Stock Picking.

Stop managing a collection of "tips." Access the ABC Framework to build a portfolio that survives cycles and compounds wealth.

Core for Stability

Booster for Alpha

Amplifier for Exponential Wealth

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Access Sapphire ABC Strategy →

Limited Capacity for New Fiduciary Partners

Pharma majors, govt to chalk out plan on export growth

MoneyWorks4Me Premium

Follow us at

MoneyWorks4Me

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.